This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Citius Pharmaceuticals’s 8K filing here.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
Recommended Stories
- Five stocks we like better than Citius Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- Market Cap Calculator: How to Calculate Market Cap
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
